<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="1.1d1" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher">REMEDIUM</journal-id><journal-title-group><journal-title>REMEDIUM</journal-title></journal-title-group><issn publication-format="print">1561-5936</issn><issn publication-format="electronic">2658-3534</issn><publisher><publisher-name>Joint-Stock Company Chicot</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1007</article-id><article-id pub-id-type="doi">10.21518/1561-5936-2020-10-28-30</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>AnviMax®: optimal drug to combat ARVI and influenza</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Kalinina</surname><given-names>Nadezhda</given-names></name><bio></bio><email>noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff id="aff-1">RM Analytics</aff><pub-date date-type="epub" iso-8601-date="2020-12-10" publication-format="electronic"><day>10</day><month>12</month><year>2020</year></pub-date><issue>10</issue><fpage>28</fpage><lpage>30</lpage><history><pub-date date-type="received" iso-8601-date="2022-03-18"><day>18</day><month>03</month><year>2022</year></pub-date></history><permissions><copyright-statement>Copyright © 2020,</copyright-statement><copyright-year>2020</copyright-year></permissions><abstract>In the epidemiological season 2019-2020, the situation with the incidence of ARVI and influenza was more critical and significantly compounded by concurrent outbreak and spread of new infection COVID-19 in the Russian Federation, resulting in increased hospitalization rates of people at risk with COVID-19 and influenza co-infection.</abstract><kwd-group xml:lang="en"><kwd>COVID-19</kwd><kwd>ARVI</kwd><kwd>influenza</kwd><kwd>COVID-19</kwd><kwd>cold-relief drugs</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>ОРВИ</kwd><kwd>грипп</kwd><kwd>противопростудные препараты</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Государственный доклад «О состоянии санитарно-эпидемиологического благополучия населения в Российской Федерации в 2015 г.». Федеральная служба по надзору в сфере защита прав потребителей и благополучия человека.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Сайт АнвиМакс®. Режим доступа: https://www.anvimax.ru/polezno-znat/stati/ gripp-i-orvi/.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Временные методические рекомендации. Лекарственная терапия острых респираторных вирусных инфекций (ОРВИ) в амбулаторной практике в период эпидемии COVID-19. Версия 2 (16.04.2020).</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Режим доступа: https://covidmaps.ru/profilaktika/paratsetamol-ot-koronavirusa.</mixed-citation></ref></ref-list></back></article>
